BWXT Earnings

BWXT reported its FY2025Q4 earnings on 2026-02-23, showcasing a revenue of 0.00 against an estimate of 819.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.91 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following BWXT's FY2025Q4 earnings announcement on 2026-02-23, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, BWXT's stock price tends to shift by an average of +0.26% in the 10 days leading up to earnings and +0.71% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate BWXT’s annual revenue to reach 837.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 1.18% and EPS estimates Revise Downward by -2.76% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BWXT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 1.18%, while EPS estimates moved Revise Downward by -2.76% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BWXT's stock price typically moves by +0.26% in the 10 days before its earnings and +0.71% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 837.00M.

The earnings call summary and Q&A session indicate strong financial metrics with raised guidance across revenue, EBITDA, EPS, and free cash flow. The Kinectrics acquisition and government/commercial operations show promising growth. Despite some risks, such as lower initial margins and delayed Project Pele delivery, the market strategy with SMRs and medical segment growth is optimistic. The positive sentiment is further supported by the strategic partnerships and opportunities in nuclear energy. Overall, the outlook suggests a positive stock price movement, likely in the 2% to 8% range.